Engineered Fc-glycosylation switch to eliminate antibody effector function

References

• Kaplon H, Muralidharan M, Schneider Z, Reichert JM. Antibodies to watch in 2020. MAbs. 2020;12:1703531.
   Google Scholar
• Bournazos S, Ravetch JV. Diversification of IgG effector functions. Int Immunol. 2017;29:303–13. doi:https://doi.org/10.1093/intimm/dxx025.
   PubMed Web of Science ®Google Scholar
• Goulet DR, Atkins WM. Considerations for the design of antibody-based therapeutics. J Pharm Sci. 2020;109:74–103. doi:https://doi.org/10.1016/j.xphs.2019.05.031.
   PubMed Web of Science ®Google Scholar
• Stein MM, Hrusch CL, Sperling AI, Ober C. Effects of an FcgammaRIIA polymorphism on leukocyte gene expression and cytokine responses to anti-CD3 and anti-CD28 antibodies. Genes Immun. 2019;20:462–72. doi:https://doi.org/10.1038/s41435-018-0038-8.
   PubMed Web of Science ®Google Scholar
• Jonnalagadda M, Mardiros A, Urak R, Wang X, Hoffman LJ, Bernanke A, Chang W-C, Bretzlaff W, Starr R, Priceman S, et al. Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy. Mol Ther. 2015;23:757–68. doi:https://doi.org/10.1038/mt.2014.208.
   PubMed Web of Science ®Google Scholar
• Gillies SD, Lan Y, Lo KM, Super M, Wesolowski J. Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors. Cancer Res. 1999;59:2159–66.
   PubMed Web of Science ®Google Scholar
• Herbener P, Schönfeld K, König M, Germer M, Przyborski JM, Bernöster K, Schüttrumpf J. Functional relevance of in vivo half antibody exchange of an IgG4 therapeutic antibody-drug conjugate. PLoS One. 2018;13:e0195823. doi:https://doi.org/10.1371/journal.pone.0195823.
   PubMed Web of Science ®Google Scholar
• Escobar-Cabrera E, Lario P, Baardsnes J, Schrag J, Durocher Y, Dixit S. Asymmetric Fc engineering for bispecific antibodies with reduced effector function. Antibodies. 2017;6:7.
   Web of Science ®Google Scholar
• Saunders KO. Conceptual approaches to modulating antibody effector functions and circulation half-life. Front Immunol. 2019;10:1296. doi:https://doi.org/10.3389/fimmu.2019.01296.
   PubMed Web of Science ®Google Scholar
• Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, Xie D, Lai J, Stadlen A, Li B, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem. 2001;276:6591–604. doi:https://doi.org/10.1074/jbc.M009483200.
   PubMed Web of Science ®Google Scholar
• Sondermann P, Huber R, Oosthuizen V, Jacob U. The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex. Nature. 2000;406:267–73. doi:https://doi.org/10.1038/35018508.
   PubMed Web of Science ®Google Scholar
• An Z, Forrest G, Moore R, Cukan M, Haytko P, Huang L, Vitelli S, Zhao JZ, Lu P, Hua J, et al. IgG2m4, an engineered antibody isotype with reduced Fc function. mAbs. 2009;1:572–79. doi:https://doi.org/10.4161/mabs.1.6.10185.
   PubMed Web of Science ®Google Scholar
• Tao MH, Morrison SL. Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J Immunol. 1989;143:2595–601.
   PubMed Web of Science ®Google Scholar
• Vafa O, Gilliland GL, Brezski RJ, Strake B, Wilkinson T, Lacy ER, Scallon B, Teplyakov A, Malia TJ, Strohl WR, et al. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations. Methods. 2014;65:114–26. doi:https://doi.org/10.1016/j.ymeth.2013.06.035.
   PubMed Web of Science ®Google Scholar
• Borrok MJ, Mody N, Lu X, Kuhn ML, Wu H, Dall’Acqua WF, Tsui P. An “Fc-silenced” IgG1 format with extended half-life designed for improved stability. J Pharm Sci. 2017;106:1008–17. doi:https://doi.org/10.1016/j.xphs.2016.12.023.
   PubMed Web of Science ®Google Scholar
• Newman R, Hariharan K, Reff M, Anderson DR, Braslawsky G, Santoro D, Hanna N, Bugelski PJ, Brigham-Burke M, Crysler C, et al. Modification of the Fc region of a primatized IgG antibody to human CD4 retains its ability to modulate CD4 receptors but does not deplete CD4(+) T cells in chimpanzees. Clin Immunol. 2001;98:164–74. doi:https://doi.org/10.1006/clim.2000.4975.
   PubMed Web of Science ®Google Scholar
• Xu D, Alegre M-L, Varga SS, Rothermel AL, Collins AM, Pulito VL, Hanna LS, Dolan KP, Parren PWHI, Bluestone JA, et al. In vitro characterization of five humanized OKT3 effector function variant antibodies. Cell Immunol. 2000;200:16–26. doi:https://doi.org/10.1006/cimm.2000.1617.
   PubMed Web of Science ®Google Scholar
• Schlothauer T, Herter S, Koller CF, Grau-Richards S, Steinhart V, Spick C, Kubbies M, Klein C, Umaña P, Mössner E, et al. Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions. PEDS. 2016;29:457–66. doi:https://doi.org/10.1093/protein/gzw040.
   Web of Science ®Google Scholar
• Armour KL, Clark MR, Hadley AG, Williamson LM. Recombinant human IgG molecules lacking Fcgamma receptor I binding and monocyte triggering activities. Eur J Immunol. 1999;29:2613–24. doi:https://doi.org/10.1002/(SICI)1521-4141(199908)29:08<2613::AID-IMMU2613>3.0.CO;2-J.
   PubMed Web of Science ®Google Scholar
• Hristodorov D, Fischer R, Joerissen H, Müller-Tiemann B, Apeler H, Linden L. Generation and comparative characterization of glycosylated and aglycosylated human IgG1 antibodies. Mol Biotechnol. 2013;53:326–35. doi:https://doi.org/10.1007/s12033-012-9531-x.
   PubMed Web of Science ®Google Scholar
• Reddy MP, Kinney CAS, Chaikin MA, Payne A, Fishman-Lobell J, Tsui P, Dal Monte PR, Doyle ML, Brigham-Burke MR, Anderson D, et al. Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4. J Immunol. 2000;164:1925–33. doi:https://doi.org/10.4049/jimmunol.164.4.1925.
   PubMed Web of Science ®Google Scholar
• Tam SH,McCarthy SG, Armstrong AA, Somani S, Wu S-J, Liu X, Gervais A, Ernst R, Saro D, Decker R et al. Functional, biophysical, and structural characterization of human IgG1 and IgG4 Fc variants with ablated immune functionality. Antibodies. 2017;6:12.
   Web of Science ®Google Scholar
• Dumet C, Pottier J, Gouilleux-Gruart V, Watier H. Insights into the IgG heavy chain engineering patent landscape as applied to IgG4 antibody development. mAbs. 2019;11:1341–50. doi:https://doi.org/10.1080/19420862.2019.1664365.
   PubMed Web of Science ®Google Scholar
• Zalevsky J, Leung IWL, Karki S, Chu SY, Zhukovsky EA, Desjarlais JR, Carmichael DF, Lawrence CE. The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates. Blood. 2009;113:3735–43. doi:https://doi.org/10.1182/blood-2008-10-182048.
   PubMed Web of Science ®Google Scholar
• Deisenhofer J. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution. Biochemistry. 1981;20:2361–70. doi:https://doi.org/10.1021/bi00512a001.
   PubMed Web of Science ®Google Scholar
• Matsumiya S, Yamaguchi Y, Saito J-I, Nagano M, Sasakawa H, Otaki S, Satoh M, Shitara K, Kato K. Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1. J Mol Biol. 2007;368:767–79. doi:https://doi.org/10.1016/j.jmb.2007.02.034.
   PubMed Web of Science ®Google Scholar
• Mizushima T, Yagi H, Takemoto E, Shibata-Koyama M, Isoda Y, Iida S, Masuda K, Satoh M, Kato K. Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans. Genes Cells. 2011;16:1071–80. doi:https://doi.org/10.1111/j.1365-2443.2011.01552.x.
   PubMed Web of Science ®Google Scholar
• Ramsland PA, Farrugia W, Bradford TM, Sardjono CT, Esparon S, Trist HM, Powell MS, Tan PS, Cendron AC, Wines BD, et al. Structural basis for Fc gammaRIIa recognition of human IgG and formation of inflammatory signaling complexes. J Immunol. 2011;187:3208–17. doi:https://doi.org/10.4049/jimmunol.1101467.
   PubMed Web of Science ®Google Scholar
• Schrodinger, LLC. The PyMOL Molecular Graphics System, Version 1.3r1; 2010.
   Google Scholar
• Jung ST, Kang TH, Kelton W, Georgiou G. Bypassing glycosylation: engineering aglycosylated full-length IgG antibodies for human therapy. Curr Opin Biotechnol. 2011;22:858–67. doi:https://doi.org/10.1016/j.copbio.2011.03.002.
   PubMed Web of Science ®Google Scholar
• Jacobsen FW, Stevenson R, Li C, Salimi-Moosavi H, Liu L, Wen J, Luo Q, Daris K, Buck L, Miller S, et al. Engineering an IgG Scaffold lacking effector function with optimized developability. J Biol Chem. 2017;292:1865–75. doi:https://doi.org/10.1074/jbc.M116.748525.
   PubMed Web of Science ®Google Scholar
• Oganesyan V, Gao C, Shirinian L, Wu H, Dall’Acqua WF. Structural characterization of a human Fc fragment engineered for lack of effector functions. Acta Crystallogr D Biol Crystallogr. 2008;64:700–04. doi:https://doi.org/10.1107/S0907444908007877.
   PubMed Web of Science ®Google Scholar
• Borrok MJ, Jung ST, Kang TH, Monzingo AF, Georgiou G. Revisiting the role of glycosylation in the structure of human IgG Fc. ACS Chem Biol. 2012;7:1596–602. doi:https://doi.org/10.1021/cb300130k.
   PubMed Web of Science ®Google Scholar
• Subedi GP, Barb AW. The structural role of antibody N-glycosylation in receptor interactions. Structure. 2015;23:1573–83. doi:https://doi.org/10.1016/j.str.2015.06.015.
   PubMed Web of Science ®Google Scholar
• Sazinsky SL, Ott RG, Silver NW, Tidor B, Ravetch JV, Wittrup KD. Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors. Proc Natl Acad Sci USA. 2008;105:20167–72. doi:https://doi.org/10.1073/pnas.0809257105.
   PubMed Web of Science ®Google Scholar
• Kayser V, Chennamsetty N, Voynov V, Forrer K, Helk B, Trout BL. Glycosylation influences on the aggregation propensity of therapeutic monoclonal antibodies. Biotechnol J. 2011;6:38–44. doi:https://doi.org/10.1002/biot.201000091.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Qiu H. The mechanistic impact of N-glycosylation on stability, pharmacokinetics, and immunogenicity of therapeutic proteins. J Pharm Sci. 2019;108:1366–77. doi:https://doi.org/10.1016/j.xphs.2018.11.029.
   PubMed Web of Science ®Google Scholar
• Bas M, Terrier A, Jacque E, Dehenne A, Pochet-Béghin V, Beghin C, Dezetter A-S, Dupont G, Engrand A, Beaufils B, et al. Fc Sialylation prolongs serum half-life of therapeutic antibodies. J Immunol. 2019;202:1582–94. doi:https://doi.org/10.4049/jimmunol.1800896.
   PubMed Web of Science ®Google Scholar
• Ju MS, Jung ST. Aglycosylated full-length IgG antibodies: steps toward next-generation immunotherapeutics. Curr Opin Biotechnol. 2014;30:128–39. doi:https://doi.org/10.1016/j.copbio.2014.06.013.
   PubMed Web of Science ®Google Scholar
• Sinclair AM, Elliott S. Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins. J Pharm Sci. 2005;94:1626–35. doi:https://doi.org/10.1002/jps.20319.
   PubMed Web of Science ®Google Scholar
• Tatsumi Y, Sasahara Y, Kohyama N, Ayano S, Endo M, Yoshida T, Yamada K, Totsuka M, Hattori M. Introducing site-specific glycosylation using protein engineering techniques reduces the immunogenicity of beta-lactoglobulin. Biosci Biotechnol Biochem. 2012;76:478–85. doi:https://doi.org/10.1271/bbb.110753.
   PubMed Web of Science ®Google Scholar
• Ohmi Y, Ise W, Harazono A, Takakura D, Fukuyama H, Baba Y, Narazaki M, Shoda H, Takahashi N, Ohkawa Y, et al. Sialylation converts arthritogenic IgG into inhibitors of collagen-induced arthritis. Nat Commun. 2016;7:11205. doi:https://doi.org/10.1038/ncomms11205.
   PubMed Web of Science ®Google Scholar
• Mimura Y, Kelly RM, Unwin L, Albrecht S, Jefferis R, Goodall M, Mizukami Y, Mimura-Kimura Y, Matsumoto T, Ueoka H, et al. Enhanced sialylation of a human chimeric IgG1 variant produced in human and rodent cell lines. J Immunol Methods. 2016;428:30–36. doi:https://doi.org/10.1016/j.jim.2015.11.009.
   PubMed Web of Science ®Google Scholar
• Anthony RM, Nimmerjahn F, Ashline DJ, Reinhold VN, Paulson JC, Ravetch JV. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science. 2008;320:373–76. doi:https://doi.org/10.1126/science.1154315.
   PubMed Web of Science ®Google Scholar
• Pagan JD, Kitaoka M, Anthony RM. Engineered Sialylation of pathogenic antibodies in vivo attenuates autoimmune disease. Cell. 2018;172(564–577):e513. doi:https://doi.org/10.1016/j.cell.2017.11.041.
   Google Scholar
• Zhou Q, Stefano JE, Manning C, Kyazike J, Chen B, Gianolio DA, Park A, Busch M, Bird J, Zheng X, et al. Site-specific antibody-drug conjugation through glycoengineering. Bioconjug Chem. 2014;25:510–20. doi:https://doi.org/10.1021/bc400505q.
   PubMed Web of Science ®Google Scholar
• Lallemand C, Liang F, Staub F, Simansour M, Vallette B, Huang L, Ferrando-Miguel R, Tovey MG. A novel system for the quantification of the ADCC activity of therapeutic antibodies. J Immunol Res. 2017;2017:3908289. doi:https://doi.org/10.1155/2017/3908289.
   PubMed Web of Science ®Google Scholar
• Clémenceau B, Congy-Jolivet N, Gallot G, Vivien R, Gaschet J, Thibault G, Vié H. Antibody-dependent cellular cytotoxicity (ADCC) is mediated by genetically modified antigen-specific human T lymphocytes. Blood. 2006;107:4669–77. doi:https://doi.org/10.1182/blood-2005-09-3775.
   PubMed Web of Science ®Google Scholar
• Qiu H, Wei R, Jaworski J, Boudanova E, Hughes H, VanPatten S, Lund A, Day J, Zhou Y, McSherry T, et al. Engineering an anti-CD52 antibody for enhanced deamidation stability. mAbs. 2019;11:1266–75. doi:https://doi.org/10.1080/19420862.2019.1631117.
   PubMed Web of Science ®Google Scholar
• Otwinowski Z, Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997;276:307–26.
   PubMed Web of Science ®Google Scholar
• McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. Phaser crystallographic software. J Appl Crystallogr. 2007;40:658–74. doi:https://doi.org/10.1107/S0021889807021206.
   PubMed Web of Science ®Google Scholar
• Adams PD, Afonine PV, Bunkóczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW, et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr. 2010;66:213–21. doi:https://doi.org/10.1107/S0907444909052925.
   PubMed Web of Science ®Google Scholar
• Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr. 2004;60:2126–32. doi:https://doi.org/10.1107/S0907444904019158.
   PubMed Web of Science ®Google Scholar